Literature DB >> 33710335

Misdiagnosed thrombocytopenia in children and adolescents: analysis of the Pediatric and Adult Registry on Chronic ITP.

Alexandra Schifferli1, Andrea Heiri2, Paul Imbach1, Susanne Holzhauer3, Markus G Seidel4, Diane Nugent5, Marc Michel6, Thomas Kühne1.   

Abstract

Primary immune thrombocytopenia (ITP) in children is a diagnosis of exclusion, but cases of secondary ITP and nonimmune thrombocytopenia (non-IT) are generally difficult to recognize in a timely fashion. We describe a pediatric population with a revised diagnosis of secondary ITP or non-IT within 24 months of follow-up. Data were extracted from the Pediatric and Adult Registry on Chronic ITP, an international multicenter registry collecting data prospectively in patients with newly diagnosed primary ITP. Between 2004 and 2019, a total of 3974 children aged 3 months to 16 years were included. Secondary ITP and non-IT were reported in 113 patients (63 female subjects). Infectious (n = 53) and autoimmune (n = 42) diseases were identified as the main causes, with median ages at diagnosis of 3.2 years (interquartile range: 1.2; 6.7 years) and 12.4 years (interquartile range: 7.6; 13.7 years), respectively. Other causes included malignancies, aplastic anemia, immunodeficiency, and drug use. Patients with malignancy and aplastic anemia had significantly higher initial platelet counts (37 and 52 × 109/L) than did those with infection or autoimmune diseases (12 and 13 × 109/L). Characteristics of patients with secondary ITP due to infection were similar to those of children with primary ITP at first presentation, indicating similar mechanisms. Significant differences were found for age, sex, comorbidities, initial bleeding, sustained need for treatment, and disease persistence for the remaining noninfectious group compared with primary ITP. Based on our findings, we propose a diagnostic algorithm that may serve as a basis for further discussion and prospective trials.
© 2021 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2021        PMID: 33710335      PMCID: PMC7993109          DOI: 10.1182/bloodadvances.2020003004

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  38 in total

Review 1.  The nontreatment of childhood ITP (or "the art of medicine consists of amusing the patient until nature cures the disease").

Authors:  P H Bolton-Maggs; R Dickerhoff; A J Vora
Journal:  Semin Thromb Hemost       Date:  2001-06       Impact factor: 4.180

2.  Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.

Authors:  Francesco Rodeghiero; Roberto Stasi; Terry Gernsheimer; Marc Michel; Drew Provan; Donald M Arnold; James B Bussel; Douglas B Cines; Beng H Chong; Nichola Cooper; Bertrand Godeau; Klaus Lechner; Maria Gabriella Mazzucconi; Robert McMillan; Miguel A Sanz; Paul Imbach; Victor Blanchette; Thomas Kühne; Marco Ruggeri; James N George
Journal:  Blood       Date:  2008-11-12       Impact factor: 22.113

Review 3.  Diagnosis and management of chronic and refractory immune cytopenias in children, adolescents, and young adults.

Authors:  Seth J Rotz; Russell E Ware; Ashish Kumar
Journal:  Pediatr Blood Cancer       Date:  2018-06-01       Impact factor: 3.167

4.  Acute idiopathic thrombocytopenic purpura--management in childhood.

Authors:  G R Buchanan; P A de Alarcon; S A Feig; G S Gilchrist; J N Lukens; C L Moertel; A R Cohen; J D Dickerman; E N Forman; B E Glader; J M Lusher
Journal:  Blood       Date:  1997-02-15       Impact factor: 22.113

5.  Primary versus secondary immune thrombocytopenia in adults; a comparative analysis of clinical and laboratory attributes in newly diagnosed patients in Southern Pakistan.

Authors:  S Sultan; S I Ahmed; S Murad; S M Irfan
Journal:  Med J Malaysia       Date:  2016-10

6.  Is Autoimmune Thrombocytopenia Itself the Primary Disease in the Presence of Second Diseases Data from a Long-Term Observation.

Authors:  Nasra Aboud; Fabian Depré; Abdulgabar Salama
Journal:  Transfus Med Hemother       Date:  2016-10-18       Impact factor: 3.747

7.  Newly diagnosed immune thrombocytopenia adults: Clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort.

Authors:  Guillaume Moulis; Johanne Germain; Thibault Comont; Natacha Brun; Claire Dingremont; Brice Castel; Sophie Arista; Laurent Sailler; Maryse Lapeyre-Mestre; Odile Beyne-Rauzy; Bertrand Godeau; Daniel Adoue
Journal:  Am J Hematol       Date:  2017-03-20       Impact factor: 10.047

8.  Duration and morbidity of newly diagnosed idiopathic thrombocytopenic purpura in children: A prospective Nordic study of an unselected cohort.

Authors:  Steen Rosthøj; Iris Hedlund-Treutiger; Jukka Rajantie; Bernward Zeller; Olafur G Jonsson; Göran Elinder; Finn Wesenberg; Jan-Inge Henter
Journal:  J Pediatr       Date:  2003-09       Impact factor: 4.406

Review 9.  The Centenary of Immune Thrombocytopenia-Part 2: Revising Diagnostic and Therapeutic Approach.

Authors:  Rita Consolini; Giorgio Costagliola; Davide Spatafora
Journal:  Front Pediatr       Date:  2017-08-21       Impact factor: 3.418

Review 10.  Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments.

Authors:  David Buchbinder; Diane J Nugent; Alexandra H Fillipovich
Journal:  Appl Clin Genet       Date:  2014-04-03
View more
  3 in total

1.  Primary immune thrombocytopenia: a 'diagnosis of exclusion'?

Authors:  Nathan Visweshwar; Irmel Ayala; Michael Jaglal; Robert Killeen; Lubomir Sokol; Damian A Laber; Arumugam Manoharan
Journal:  Blood Coagul Fibrinolysis       Date:  2022-07-29       Impact factor: 1.061

Review 2.  Understanding Immune Thrombocytopenia: Looking Out of the Box.

Authors:  Alexandra Schifferli; Franco Cavalli; Bertrand Godeau; Howard A Liebman; Mike Recher; Paul Imbach; Thomas Kühne
Journal:  Front Med (Lausanne)       Date:  2021-06-24

3.  First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland.

Authors:  C R Simpson; T Shi; E Vasileiou; S V Katikireddi; S Kerr; E Moore; C McCowan; U Agrawal; S A Shah; L D Ritchie; J Murray; J Pan; D T Bradley; S J Stock; R Wood; A Chuter; J Beggs; H R Stagg; M Joy; R S M Tsang; S de Lusignan; R Hobbs; R A Lyons; F Torabi; S Bedston; M O'Leary; A Akbari; J McMenamin; C Robertson; A Sheikh
Journal:  Nat Med       Date:  2021-06-09       Impact factor: 53.440

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.